Can n-3 PUFA reduce cardiac arrhythmias? Results of a clinical trial

  • P. S
  • M. W
  • 3


    Mendeley users who have this article in their library.
  • N/A


    Citations of this article.


Dietary n-3 polyunsaturated fatty acids (PUFA) derived from fatty fish or fish oil may reduce the incidence of lethal myocardial infarction and sudden cardiac death. This might be due to a prevention of fatal cardiac arrhythmias. So far, however, only few clinical data are available being adequate to define indications for an antiarrhythmic treatment with n-3 PUFA. In a randomized, double-blind, placebo-controlled study 65 patients with cardiac arrhythmias without coronary heart disease or heart failure were subdivided into 2 groups. One group (n=33) was supplemented with encapsulated fish oil (3g/day, equivalent to 1g/day of n-3 PUFA) over 6 months. The other group (n=32) was given 3g/day of olive oil as placebo. In the fish oil group a decrease of serum triglycerides, total cholesterol, LDL cholesterol, plasma free fatty acids and thromboxane B2 as well as an increase of HDL cholesterol were observed. Moreover, a reduced incidence of atrial and ventricular premature complexes, couplets and triplets were documented. Accordingly, higher grades of Lown's classification switched to lower grades at the end of the dietary period. No changes were seen in the placebo group. The data indicate an antiarrhythmic action of n-3 PUFA under conditions of clinical practice which might help to explain the reduced incidence of fatal myocardial infarction and sudden cardiac death in cohorts on a fish-rich diet or supplemented with n-3 PUFA. Further studies elucidating the possible link between the reduced incidence of cardiac arrhythmias and sudden cardiac death by dietary intake of n-3 PUFA are warranted. 2004 Elsevier Ltd. All rights reserved.

Author-supplied keywords

  • *fish oil/ct [Clinical Trial]
  • *fish oil/do [Drug Dose]
  • *fish oil/dt [Drug Therapy]
  • *fish oil/pd [Pharmacology]
  • *heart arrhythmia/dt [Drug Therapy]
  • *polyunsaturated fatty acid/ct [Clinical Trial]
  • *polyunsaturated fatty acid/do [Drug Dose]
  • *polyunsaturated fatty acid/dt [Drug Therapy]
  • *polyunsaturated fatty acid/pd [Pharmacology]
  • adult
  • article
  • cholesterol blood level
  • cholesterol/ec [Endogenous Compound]
  • clinical trial
  • concentration (parameters)
  • controlled clinical trial
  • controlled study
  • dietary intake
  • dose response
  • double blind procedure
  • drug mechanism
  • fatty acid blood level
  • fatty acid/ec [Endogenous Compound]
  • female
  • heart atrium
  • heart failure
  • heart ventricle
  • high density lipoprotein cholesterol/ec [Endogenou
  • human
  • ischemic heart disease
  • low density lipoprotein cholesterol/ec [Endogenous
  • major clinical study
  • male
  • medical documentation
  • olive oil
  • placebo
  • priority journal
  • randomized controlled trial
  • serum
  • thromboxane B2/ec [Endogenous Compound]
  • triacylglycerol blood level
  • triacylglycerol/ec [Endogenous Compound]

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document


  • Singer P.

  • Wirth M.

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free